{
  "ticker": "IBX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969341",
  "id": "02969341",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250715",
  "time": "0926",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt23fwr9kjz3.pdf",
  "summary": "- **Clinical Trial Update**: FDA meeting on MagSense\u00ae HER2 Breast Cancer Phase 2 trial concluded positively, no issues identified.  \n- **IND Timeline**: Investigational New Drug (IND) application expected Q3 2025.  \n- **Manufacturing**: MagSense\u00ae HER2 Imaging Agent production to be fast-tracked, completion targeted for Q3 2025.  \n\n**Key Impact**: Progress in regulatory and manufacturing milestones de-risks Phase 2 trial commencement, a material catalyst for valuation.",
  "usage": {
    "prompt_tokens": 1508,
    "completion_tokens": 105,
    "total_tokens": 1613,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:50:05.961898"
}